摘要
目的观察埃索美拉唑联合西沙必利治疗反流性食管炎（RE）的临床疗效，并探讨其相关的临床意义。方法收集我院消化内科2010年12月-2011年12月收治的反流性食管炎患者94例，94例患者随机分为埃索美拉唑治疗组（A，／7,=47）和埃索美拉唑联合西沙必利治疗组（B，n=47）。对照两组的临床疗效、不良反应发生率以及复发率。结果A组B组治疗的有效率分别为91．5％和72．3％，B组的临床疗效显著优于A组（P〈0．05）。A组的临床不良反应发生率为4．3％，B组的临床不良反应发生率为6．4％，两组间差异无统计学意义（P〉0．05）。A组的复发率为40．4％，B组的复发率为23．4％，两组间差异有统计学意义（P〈0．05）。结论埃索美拉唑联合西沙必利治疗反流性食管炎临床疗效显著，复发率以及临床不良反应率低，值得临床推广应用。
Objective To investigate the clinic efficacy of esomeprazole combined with cisapride in the treatment of reflux esophagitis （RE） and explore its clinic significants. Methods A total of 94 RE patients were enrolled in this study. The patients were randomly devided into two groups ： esomeprazole treatment group （ A, n = 47 ） and esomeprazole combined with cisapfide treatment group（ B, n =47）. The clinic and side effects of drugs and recurrence rate were compared between the two groups. Restilts The clinic effective rate in group A and B was 91.5% and 72.3%, respectively. The clinic effective rate in group B is higher than that in group A（ P 〈0.05）. The rate of clinical adverse reactions in group A and B was 4.3% and 6.4% , respectively. There was not significant difference between the two groups （P 〉 0.05 ）. The recurrence rate in group A and B was 40.4% and 23.4%, respectively. There was significant difference between the two groups（ P 〈 0.05 ）. Conclusion Esomeprazole Combined with cisapride showed effectively in treating RE with lower adverse reactions and less recurrence, and which was worthy to promote the clinical application.
出处
《四川医学》
CAS
2013年第4期569-570,共2页
Sichuan Medical Journal
